Section Arrow
AVBP.NASDAQ
- ArriVent BioPharma
Quotes are at least 15-min delayed:2026/07/15 13:24 EDT
Regular Hours
Last
 32.82
+0.28 (+0.86%)
Day High 
33.475 
Prev. Close
32.54 
1-M High
35.83 
Volume 
84.61K 
Bid
32.78
Ask
32.86
Day Low
32.25 
Open
32.52 
1-M Low
29.13 
Market Cap 
1.52B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 33.95 
20-SMA 33.2 
50-SMA 30.76 
52-W High 35.83 
52-W Low 16.1 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.38/-3.19
Enterprise Value
1.52B
Balance Sheet
Book Value Per Share
6.96
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
VIVSVivoSim Lab Inc0.967+0.1322+15.84%0.47PE
LIMNLiminatus Pharma Inc0.1149+0.0114+11.01%-- 
IOVAIovance Biotherapeutics4.37+0.44+11.20%-- 
ERNAErnexa Therapeutics Inc.6.52+0.46+7.59%0.01PE
RXRXRecursion Pharmaceuticals3.3467+0.0067+0.20%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.